TEDA-Made Multi-Center Clinical Trial for Domestic "HeartConII" Launched

Recently, co-hosted by ROCOR MEDICAL Technology Co., Ltd. and TEDA International Cardiovascular Hospital, the launch meeting for the Multi-center Clinical Trial of HeartConII and a seminar on postoperative patient management for implantable left ventricular assist systems (LVADs) were held in Tianjin, marking the formal entry of China’s fully self-developed, magnetically levitated artificial heart into the critical stage of clinical validation.

"HeartConII" is currently the world’s smallest magnetically levitated artificial heart, weighing only 75 grams. With its compact size and lightweight pump, the device utilizes world-first non-inductive automatic control technology and boasts the world’s best hemocompatibility. It is designed to accommodate patients ranging from children to adults with very high body weight, filling a global gap for implantable artificial hearts suitable for small-stature heart failure patients.

Since TEDA International Cardiovascular Hospital and the China Academy of Launch Vehicle Technology joined forces in 2009 to develop the artificial heart, 17 years of research have led to a leap from "HeartConI" to "HeartConII". As a breakthrough in both fundamental innovation and structural redesign, the core technology of "HeartConII" has reached a world-leading level.

Recently, the team at TEDA International Cardiovascular Hospital successfully completed its 100th artificial heart implantation. The patient, who was also the first to be enrolled in the "HeartConII" clinical trial, is recovering well after surgery. This successful case fully validates the superior adaptability and safety of "HeartConII", bringing new therapeutic hope to patients with low body weight, small stature, and end-stage heart failure.